Expression levels of GSDMB and ORMDL3 are associated with relapsing-remitting multiple sclerosis and IKZF3 rs12946510 variant

被引:0
|
作者
Stefanovic, Milan [1 ]
Stojkovic, Ljiljana [1 ]
Zivotic, Ivan [1 ]
Dincic, Evica [2 ]
Stankovic, Aleksandra [1 ]
Zivkovic, Maja [1 ]
机构
[1] Univ Belgrade, Inst Nucl Sci Vinea Natl Inst Republ Serbia, Lab Radiobiol & Mol Genet 080, POB 522, Belgrade 11000, Serbia
[2] Mil Med Acad, Clin Neurol, Belgrade, Serbia
关键词
Multiple sclerosis; ORMDL3; GSDMB; IKZF3; 17q12-21; rs12946510; DNA METHYLATION; ORMDL3; AIOLOS; DISABILITY; INSIGHTS;
D O I
10.1016/j.heliyon.2024.e25033
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Multiple sclerosis (MS), a noncurable autoimmune neurodegenerative disease, requires constant research that could improve understanding of both environmental and genetic factors that lead to its occurrence and/or progression. Recognition of the genetic basis of MS further leads to an investigation of the regulatory role of genetic variants on gene expression. Among risk variants for MS, Ikaros zinc finger 3 (IKZF3) gene variant rs12946510 was identified as one of the top -ranked and the expression quantitative trait loci (eQTL) for genes residing in chromosomal locus 17q1221. The study aimed to investigate the association of gene expression of the immunologically relevant genes, which map to indicated locus, ORMDL3, GSDMB, and IKZF3, with MS and rs12946510 genotype, taking into account disease phase, clinical parameters of disease progression, and severity and immunomodulatory therapy. We used TaqMan (R) technology for both allelic discrimination and gene expression determination in 67 relapsing MS patients and 50 healthy controls. Decreased ORMDL3 and GSDMB mRNA levels had significant associations with MS and rs12946510 TT rare homozygote among patients. Significant positive correlations between ORMDL3 and GSDMB mRNA expression were observed in both patients and controls. We detected the significant between -effect of sex and rs12946510 on the expression of ORMDL3 in the patient group and interferon beta therapy and rs12946510 on GSDMB expression. Our results show the association of ORMDL3 and GSDMB mRNA expression with the clinical manifestation of MS and confirm that IKZF3 rs12946510 exerts the eQTL effect on both genes in multiple sclerosis. Besides providing novel insight related to MS phases and interferon beta therapy, the study results confirm previous studies on regulatory genetic variants, autoimmunity, and MS.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] 3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis
    Illes, Z.
    Farago, B.
    Peterfalvi, A.
    Magyari, L.
    Pozsonyi, E.
    Rozsa, C.
    Komoly, S.
    Melegh, B.
    MULTIPLE SCLEROSIS, 2007, 13 : S202 - S202
  • [32] Clinical activity in relapsing-remitting multiple sclerosis is associated with a decrease in RGC-32 mRNA expression in peripheral blood
    Tegla, C.
    Cudrici, C.
    Nguyen, V.
    Vlaicu, S.
    Costello, K.
    Royal, W.
    Bever, C.
    Rus, V.
    Rus, H.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S189 - S189
  • [33] Expression analysis of vitamin D receptor-associated long noncoding RNAs in patients with relapsing-remitting multiple sclerosis
    Naiini, Mahdis Rahimi
    Saeidi, Kolsoum
    Azarian, Arezoo
    Bahramzadeh, Kiana
    Nazari-robati, Mahdieh
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (02): : 107 - 112
  • [34] SOCS3 expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients modulates leptin sensitivity
    Frisullo, G
    Mirabella, M
    Morosetti, R
    Sancricca, C
    Angelucci, F
    Caggiula, M
    Patanella, AK
    Nociti, V
    Tonali, RA
    Batocchi, AP
    MULTIPLE SCLEROSIS, 2005, 11 : S126 - S127
  • [35] SOCS3 expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients modulates leptin sensitivity
    Frisullo, G
    Mirabella, M
    Morosetti, R
    Sancricca, C
    Angelucci, F
    Caggiula, M
    Patanella, AK
    Nociti, V
    Tonali, PA
    Batocchi, AP
    NEUROLOGY, 2005, 64 (06) : A195 - A195
  • [36] Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
    Selmaj, K.
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Arnold, D.
    Giovannoni, G.
    Sweetser, M.
    Novas, M.
    Raghupathi, K.
    Dawson, K.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S451
  • [37] DECREASED CD3-MEDIATED INTERFERON-GAMMA PRODUCTION IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
    BROD, SA
    KHAN, M
    BRIGHT, J
    SRIRAM, S
    MARSHALL, GJ
    HENNINGER, EM
    KERMAN, RH
    WOLINSKY, JS
    ANNALS OF NEUROLOGY, 1995, 37 (04) : 546 - 549
  • [38] Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina
    Carra, A.
    Onaha, P.
    Luetic, G.
    Burgos, M.
    Crespo, E.
    Deri, N.
    Halfon, M.
    Jaacks, G.
    Lopez, A.
    Sinay, V.
    Vrech, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (04) : 386 - 393
  • [39] LONG-TERM INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - 3 YEARS EXPERIENCE
    ACHIRON, A
    ZIV, I
    GILAD, R
    DJALDETTI, R
    ZOLDAN, Y
    SAROVAPINHAS, I
    MELAMED, E
    ANNALS OF NEUROLOGY, 1993, 34 (02) : 275 - 275
  • [40] CD8+Foxp3+ T cells in peripheral blood of relapsing-remitting multiple sclerosis patients
    Frisullo, Giovanni
    Nociti, Viviana
    Iorio, Raffaele
    Plantone, Domenico
    Patanella, A. Katia
    Tonali, Pietro A.
    Batocchi, Anna Paola
    HUMAN IMMUNOLOGY, 2010, 71 (05) : 437 - 441